Since its discovery in the 1980s, the family of lipid kinases termed phosphoinositide 3-kinases (PI3Ks) has been found to have key regulatory roles in many cellular processes, including cell survival, proliferation and differentiation [1] [2] [3] . As major effectors downstream of receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), PI3Ks transduce signals from various growth factors and cytokines into intracellular messages by generating phospholipids, which activate the serinethreonine protein kinase AKT (also known as protein kinase B (PKB)) and other downstream effector pathways (FIG. 1) . The tumour suppressor PTEN (phosphatase and tensin homologue) is the most important negative regulator of the PI3K signalling pathway 4,5 . Recent human cancer genomic studies have revealed that many components of the PI3K pathway are frequently targeted by germline mutations or somatic mutations in a broad range of human cancers. These findings, and the fact that PI3K and other kinases in the PI3K pathway are amenable to pharmacological intervention, make this pathway one of the most attractive targets for therapeutic intervention in cancer 6 .
Class IA PI3Ks. These are heterodimers consisting of a p110 catalytic subunit and a p85 regulatory subunit (FIG. 2a) . The regulatory subunit mediates receptor binding, activation, and localization of the enzyme. In mammals, the genes PI3K regulatory subunit 1 (PIK3R1), PIK3R2 and PIK3R3 encode p85α (and its splice variants p55α and p50α), p85β and p55γ regulatory subunits, respectively. This group of subunits is collectively called p85 (reviewed in ReFs 2, 3) . In response to growth factor stimulation and the subsequent activation of RTKs, PI3K is recruited to the membrane by direct interaction of its p85 subunit with tyrosine phosphate motifs on activated receptors (for example, platelet-derived growth factor receptor) or to adaptor proteins associated with the receptors (for example, insulin receptor substrate 1 (IRS1)). The activated p110 catalytic subunit generates phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), which activates multiple downstream signalling pathways (FIGs 1, 2b) .
Class IB PI3Ks. The class IB PI3K that has been fully characterized to date is a heterodimer composed of the catalytic subunit p110γ and the regulatory subunit p101 (ReF. 8) (FIG. 2a) . Two other regulatory subunits of class IB PI3Ks, p84 and p87 PI3K adaptor proteins, have recently been described 9, 10 . p110γ is activated directly by GPCRs through interaction of its regulatory subunit with the Gβγ subunit of trimeric G proteins 8 . p110γ is mainly expressed in leukocytes but is also found in the heart, pancreas, liver and skeletal muscle [11] [12] [13] . Germline mutation A heritable change in the DNA that occurred in a germ cell or the zygote at the single-cell stage. When transmitted to the next generation, a germline mutation is incorporated in every cell of the body.
Departments of Cancer

Somatic mutation
Also referred to as an 'acquired mutation', this is an alteration in DNA that occurs in a somatic cell, in contrast to a mutation in a germ cell. Class II PI3Ks. These consist of a single catalytic subunit, which preferentially uses phosphatidylinositol or phosphatidylinositol-4-phosphate (PtdIns4P) as substrates 2, 3 (FIG. 2a) . There are three class II PI3K isoforms -PI3KC2α, PI3KC2β and PI3KC2γ -which can be activated by RTKs, cytokine receptors and integrins; however, the specific cellular functions of this family remain unclear.
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Class III PI3K. The class III PI3K consists of a single catalytic subunit, vPS34 (homologue of the yeast vacuolar protein sorting-associated protein 34; also known as PIK3C3). vPS34 only produces PtdIns3P, which is an important regulator of membrane trafficking (reviewed in ReF. 3) . vPS34 has been shown to function as a nutrient-regulated lipid kinase that mediates signalling through mammalian target of rapamycin (mTOR), indicating a potential role in regulating cell growth 14 . Interestingly, it has also been implicated as an important regulator of autophagy (reviewed in ReF. 14) , a cellular response to nutrient starvation.
PTEN.
The phospholipid PtdIns(3,4,5)P 3 , which is generated by activated class I PI3Ks, is the key second messenger that drives several downstream signalling cascades that regulate cellular processes (FIG. 1) . The cellular levels of PtdIns(3,4,5)P 3 are tightly regulated by the opposing activity of PTEN. PTEN, an important tumour suppressor, functionally antagonizes PI3K activity through its intrinsic lipid phosphatase activity that reduces the cellular pool of PtdIns(3,4,5)P 3 by converting PtdIns(3,4,5)P 3 back to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) (FIG. 2b) . loss of PTEN results in unrestrained signalling by the PI3K pathway, leading to cancer (reviewed in ReF. 4 ).
Figure 1 | The class i Pi3K signalling pathway.
Following growth factor stimulation and subsequent activation of receptor tyrosine kinases (RTKs), class IA phosphoinositide 3-kinases (PI3Ks), consisting of p110α-p85, p110β-p85 and p110δ-p85, are recruited to the membrane by direct interaction of the p85 subunit with the activated receptors (for example, platelet-derived growth factor receptor) or by interaction with adaptor proteins associated with the receptors (for example, insulin receptor substrate 1). The activated p110 catalytic subunit converts phosphatidylinositol-4,5-bis phosphate (PtdIns(4,5)P 2 ) to phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ) at the membrane, providing docking sites for signalling proteins that have pleckstrin homology domains, including putative 3-phosphoinositide-dependent kinase 1 (PDPK1) and serine-threonine protein kinase AKT (also known as protein kinase B). PDPK1 phosphorylates and activates AKT, which elicits a broad range of downstream signalling events. The class IB PI3K (p110γ-p101) can be activated directly by G protein-coupled receptors (GPCRs) through interaction with the Gβγ subunit of trimeric G proteins. The p110β and p110δ subunits can also be activated by GPCRs. PTEN (phosphatase and tensin homologue) antagonizes the PI3K action by dephosphorylating PtdIns(3,4,5)P 3 . BAD, BCL2-associated agonist of cell death; FOXO1, forkhead box O1 (also known as FKHR); GSK3β, glycogen synthase kinase 3β; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; PKC, protein kinase C; RAC1, RAS-related C3 botulinum toxin substrate 1; SGK, serum and glucocorticoid-regulated kinase; S6K, ribosomal protein S6 kinase; LPA, lysophosphatidic acid. Class I PI3Ks Figure 2 | The Pi3K family and phosphatidylinositol-3,4,5-trisphosphate generation. a | Phosphoinositide 3-kinases (PI3Ks) are divided into three classes according to their structural characteristics and substrate specificity. Class IA PI3Ks are heterodimers consisting of a p110 catalytic subunit and a p85 regulatory subunit. There are three p110 catalytic isoforms: p110α, p110β and p110δ. Whereas the expression of p110δ is largely restricted to the immune system, p110α and p110β are ubiquitously expressed 3, 8 . The p110 catalytic isoforms are highly homologous and share five distinct domains: an amino-terminal p85-binding domain (p85 BD), which interacts with the p85 regulatory subunit; a RAS-binding domain (RAS BD), which mediates activation by members of the RAS family of small GTPases; a putative membrane-binding domain, C2; the helical domain; and the carboxy-terminal kinase catalytic domain. There are also three p85 isoforms: p85α (and its splice variants p55α and p50α), p85β and p55γ. They share three core domains, including a p110-binding domain called the inter-Src homology 2 (iSH2) domain, flanked by two SH2 domains. The two longer isoforms, p85α and p85β, have an SH3 domain and a BCR homology domain (BHD) located in their extended N-terminal regions. In the basal state, p85 binds to the N-terminus of the p110 subunit through its iSH2 domain, inhibiting its catalytic activity 7, 8 . Class IB PI3K is a heterodimer composed of the catalytic subunit p110γ and the regulatory subunit p101. p110γ is mainly expressed in leukocytes and can be activated directly by G protein-coupled receptors 8 . Class II PI3Ks are monomers with a single catalytic subunit. There are three class II PI3K isoforms: PI3KC2α, PI3KC2β and PI3KC2γ, each of which has a divergent N-terminus followed by a RAS-binding domain, a C2 domain, a helical domain and a catalytic domain, with PX (Phox homology) and C2 domains at the C-termini (reviewed in ReFs 2, 3) . The class III PI3K consists of a single catalytic subunit, VPS34 (homologue of the yeast vacuolar protein sorting-associated protein 34). b | Phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ) is an important lipid second messenger that regulates many cellular processes. Class I PI3Ks phosphorylate the inositol ring of phosphatidylinositol-4,5-trisphosphate (PtdIns(4,5)P 2 ) on the 3 position, to generate PtdIns(3,4,5)P 3 . PTEN (phosphatase and tensin homologue) is a lipid phosphatase that removes phosphate on the 3 position of PtdIns(3,4,5)P 3 and converts it back to PtdIns(4,5)P 2 . Gβγ BD, G protein βγ subunit-binding domain.
AKT. This serine-threonine protein kinase is expressed as three isoforms -AKT1, AKT2 and AKT3 -which are encoded by the genes PKBα, PKBβ and PKBγ, respectively (reviewed in ReFs 1, 15) . The three isoforms share a similar structure: an amino-terminal pleckstrin homology domain, a central serine-threonine catalytic domain, and a small carboxy-terminal regulatory domain. AKT activation is initiated by translocation to the plasma membrane, which is mediated by docking of the pleckstrin homology domain in the N-terminal region of AKT to PtdIns(3,4,5) P 3 on the membrane. The resulting conformational change in AKT exposes two crucial amino-acid residues for phosphorylation 16, 17 . Both phosphorylation events -on T308 by 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and on S473 by putative PDPK2 -are required for full activation of AKT 1, 16, 17 . A number of potential PDPK2s have been identified, including IlK (integrinlinked kinase), protein kinase C b2, DNA-dependent protein kinase (DNA-PK), ATm (ataxia telangiectasia mutated) and AKT itself 15 ; however, it is currently thought that the mTOR-rictor (rapamycin insensitive companion of mTOR) complex (mTORC2) is the primary source of PDPK2 activity under most circumstances 18 . Once AKT has been phosphorylated and activated, it phosphorylates many other proteins -for example, glycogen synthase kinase 3 and FOXOs (the forkhead box family of transcription factors) -thereby regulating a wide range of cellular processes involved in protein synthesis, cell survival, proliferation and metabolism (reviewed in ReFs 15, 19) .
mTOR. mTOR plays a crucial part in the regulation of cell growth and proliferation by monitoring nutrient availability, cellular energy levels, oxygen levels and mitogenic signals (reviewed in ReF. 20) . It belongs to a group of serine-threonine protein kinases of the PI3K superfamily, referred to as class Iv PI3Ks, including ATm, ataxia telangiectasia and RAD3-related protein (ATR), DNA-PK and SmG1 (SmG1 homologue, phosphatidylinositol 3-kinase-related kinase). mTOR exists in two distinct complexes -mTORC1 and mTORC2. The mTORC1 complex is composed of the mTOR catalytic subunit, regulatory associated protein of mTOR (raptor), prolinerich AKT substrate 40 kDa (PRAS40) and the protein mlST8 (reviewed in ReFs 20, 21) . mTORC2 is composed of mTOR, rictor, mammalian stress-activated protein kinase interacting protein 1 (mSIN1) and mlST8 (ReF. 21 ). AKT can activate mTOR by phosphorylating both PRAS40 and tuberous sclerosis 2 protein (TSC2; also known as tuberin) to attenuate their inhibitory effects on mTORC1 . The discovery of the association of mTORC1 with the bipartite complex TSC1 and TSC2 of tumour suppressor proteins provided a molecular link between mTOR and cancer (reviewed in ReF. 25) . The most extensively characterized downstream targets of mTORC1 are ribosomal protein S6 kinase 1 (S6K1; also known as p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), both of which are crucial to the regulation of protein synthesis (reviewed in ReF. 26 ). Thus, activation of mTOR may provide tumour cells with a growth advantage by promoting protein synthesis. when bound to rictor in the mTORC2 complex, mTOR functions as a PDPK2 to phosphorylate AKT 18 .
Linking the PI3K pathway to human cancers Although PI3K was originally characterized two decades ago through its binding to oncogenes and activated RTKs (reviewed in ReF. 27) , its association with human cancer was not established until the late 1990s, when it was shown that the tumour suppressor PTEN acts as a phosphatase that is specific for the lipid products of PI3K. Recent comprehensive cancer genomic analyses have revealed that many components of the PI3K pathway are frequently mutated or altered in common human cancers [28] [29] [30] [31] [32] [33] , underscoring the importance of this pathway in cancer.
The discovery of the PTEN tumour suppressor links PI3K to human cancer. Germline mutations in the PTEN gene cause various inherited cancer predisposition syndromes, including Cowden's syndrome and Bannayan-Riley-Ruvalcaba's syndrome 34 . Somatic loss of PTEN by gene mutation or deletion frequently occurs in common human tumours (TABLe 1) . The discovery that the tumour suppressor PTEN works by antagonizing PI3K established the first direct link between PI3K activation and human cancer. Although PTEN possesses protein tyrosine phosphatase activity 35 , it is also a lipid phosphatase capable of specifically removing the 3′ phosphate from PtdIns(3,4,5)P 3 . This action is essential to its function as a tumour suppressor (reviewed in ReFs 36, 37) . unsurprisingly, PI3K signalling was found to be hyperactive in PTEN-null tumour cell lines and primary tumours 5 . The human disease phenotypes associated with PTEN loss have been recapitulated in genetic mouse models (reviewed in ReFs 36, 38) . Heterozygous loss or tissue-specific homozygous loss of PTEN in the mouse leads to hyperplastic proliferation and neoplastic transformation in several tissues [39] [40] [41] [42] [43] .
Mutations of class IA PI3Ks frequently occur in human tumours. The importance of PI3Ks in cancer was confirmed by the discovery that the PI3K catalytic subunit α-isoform gene (PIK3CA), which encodes p110α, is frequently mutated in some of the most common human tumours [29] [30] [31] [32] 44 (TABLe 1) . These genetic alterations of PIK3CA consist exclusively of somatic missense mutations clustered in two 'hotspot' regions in exons 9 and 20, corresponding to the helical and kinase domains of p110α, respectively. Two of the most frequent PIK3CA mutations, E545K and H1047R, have been shown to increase PtdIns(3,4,5)P 3 levels, activate AKT signalling and induce cellular transformation 2, [45] [46] [47] [48] . Although the exact molecular mechanisms by which these mutations activate p110α have not been determined, current data suggest an ablation of the inhibitory effect that is brought about by interaction of p110α with p85 (ReFs 45, 49, 50) . This notion was supported by two recent structural studies of the p110α-p85α complex 51, 52 . Recent cancer genomic analysis of human glioblastomas showed that the PIK3R1 gene, which encodes the p85α regulatory subunit, was mutated in up to 10% of tumours analysed, making it one of the most frequently altered glioblastoma cancer genes 30, 31 . Interestingly, although PIK3CA mutations were also found in ~7% of glioblastomas in the same cohort, they were mutually exclusive of PIK3R1 mutations 30 . The presence of somatic mutations in PIK3R1 was also previously reported in primary human colon and ovarian tumours and in one patient with glioblastoma 53, 54 . Notably, most of these mutations are located within the inter-Src homology 2 (iSH2) domain of p85α and are thought to disrupt the inhibitory contact of p85α with p110, leading to constitutive PI3K activity 30, 53, 54 . In contrast to PIK3CA, cancer-specific mutations have not been found in the PIK3CB gene, which encodes p110β, even though several groups have shown that it can act as an oncogene in model systems 2, 45 . A recent study has shown that it may be more difficult to activate p110β than p110α by missense mutation 45 , perhaps because p110β has a lower lipid kinase activity than p110α 55 . However, PIK3CB has been found to be amplified in some primary tumours and cancer cell lines 56, 57 .
AKT and PDPK1 in human cancer. Amplification of AKT1 and AKT2 has been reported in various tumour types (TABLe 1) . Recently, an activating mutation in the pleckstrin homology domain of AKT1 (E17K) -which results in growth factor-independent membrane translocation of AKT and increased AKT phosphorylation levels 58, 59 -was identified in melanoma, breast, colorectal and ovarian cancers 44, 58, 59 . Interestingly, the equivalent mutation was also detected in AKT3 in clinical specimens of melanoma as well as in melanoma cell lines 59 . unlike PI3K and AKT, there is only a single PDPK1 isoform in mammals (reviewed in ReF. 60) . Although mutations in PDPK1 are rarely found in human cancer (two cases in colorectal cancer and one in glioma have been reported thus far 61 ), amplification or overexpression of PDPK1 was found in ~20% of breast cancers 57 .
Current targeting of nodes in the PI3K pathway
Activation of the PI3K signalling pathway contributes to cell proliferation, survival and motility as well as angiogenesis, which are responsible for all the important aspects of tumorigenesis. For this reason, many pharmaceutical companies and academic laboratories are actively developing inhibitors that target PI3K and other key components in the pathway (FIGs 3,4; TABLe 2).
Targeting PI3K. wortmannin and lY294002 are two well-known, first-generation PI3K inhibitors. wortmannin is a natural product isolated from Penicillium wortmannin that binds irreversibly to PI3K enzymes by covalent modification of a lysine residue that is necessary for catalytic activity. lY294002 was the first synthetic drug-like smallmolecule inhibitor to be capable of reversibly targeting PI3K family members at concentrations in the micromolar range. However, both wortmannin and lY294004 show little or no selectivity for individual PI3K isoforms and have considerable toxicity in animals (reviewed in ReFs 62, 63) . Despite their limitations, the preclinical studies of these broad-spectrum PI3K inhibitors have greatly contributed to our understanding of the biological importance of PI3K signalling and provided a platform for the discovery of novel PI3K inhibitors.
Numerous PI3K inhibitor chemotypes, some of which show differential isoform selectivity, have been described 63, 64 . A recent study 64 presented a comparison of isoform selectivity profiles among a collection of potent and structurally diverse PI3K inhibitors. The data underlined a crucial role for p110α in insulin signalling and also provided important insights for the development of isoform-selective PI3K inhibitors. Subsequently, PI-103, a p110α-specific inhibitor, was shown to have a potent effect in blocking PI3K signalling in glioma cells through its ability to inhibit both p110α and mTOR 65 . The seemingly off-target effects of PI-103 on mTOR complexes opened a new avenue in the search for an effective cancer therapy strategy that uses a combined inhibition of mTOR and PI3K.
Numerous PI3K-targeted compounds are being introduced into clinical trials (FIG. 4 ; TABLe 2), many of which are dual PI3K-mTOR inhibitors. BEZ235 is an imidazoquinazoline derivative that inhibits multiple class I PI3K isoforms and mTOR kinase activity by binding to the ATP-binding pocket 66 . Preclinical data show that BEZ235 has strong anti-proliferative activity against tumour xenografts that have abnormal PI3K signalling, including loss of PTEN function or gainof-function PI3K mutations 67 . BEZ235 has entered Phase I clinical trials in patients with solid tumours (reviewed in ReF. 68) . BGT226 is another potent pan-PI3K-mTOR inhibitor that has entered Phase I clinical trials. BKm120, unlike BEZ235 and BGT226, is selective for class I PI3K enzymes and has no mTOR inhibitory activity, and has just entered Phase I clinical trials. The class I PI3K inhibitors Xl765 (which also targets mTOR) and Xl147 are currently under Phase I clinical investigation for treatment of solid tumours. Both are derivatives of quin oxaline, as revealed by their recently disclosed structures 63 . GDC0941 is a derivative of PI-103 that is active against all isoforms of class I PI3Ks in the nanomolar range. It displayed potent antitumour activity in preclinical xenograft tumours and is under Phase I trial in patients with advanced solid tumours or lymphoma. GSK1059615, another clinical candidate that targets PI3K, has recently entered clinical trial in patients with solid tumours or lymphoma (FIG. 4; TABLe 2 ).
SF1126 is a covalent conjugate of lY294002 with an arg-gly-asp peptide, designed for increased solubility and enhanced delivery of the active drug to the tumour 69 . In preclinical studies, SF1126 was found to have potent inhibitory effects on cell growth, proliferation and angiogenesis, and had lower toxicity than the parent lY294002. SF1126 has entered a Phase I clinical trial as a PI3K-mTOR inhibitor in a wide range of solid tumour cancers (FIG. 4; TABLe 2 ).
Numerous compounds that preferentially target selected isoforms of class I PI3Ks are also under development. For example, PX-866 targets p110α, p110δ and p110γ with half-maximal inhibitory concentration (IC 50 ) values in the low nanomolar range 70 , and CAl-101 is a p110γ-selective inhibitor under Phase I clinical study in patients with relapsed or refractory haematological malignancies (FIG. 4; TABLe 2 ).
Targeting AKT. AKT is the most crucial proximal node downstream of the RTK-PI3K complex, and is therefore another attractive therapeutic target. Several AKT inhibitors have been developed, which can be grouped into various classes, including lipid-based phosphatidylinositol analogues, ATP-competitive inhibitors, and allosteric inhibitors. The most clinically advanced inhibitor, perifosine, is a lipid-based phosphatidylinositol analogue that targets the pleckstrin homology domain of AKT, which prevents AKT from binding to PtdIns(3,4,5)P 3 and undergoing membrane translocation 71 . It is currently in clinical trials as a single agent or in combination with various drugs to treat multiple types of cancers (FIG. 4;  74 . most ATP-competitive small-molecule AKT inhibitors are non-selective, targeting all three AKT isoforms. GSK690693 is an ATP-competitive AKT kinase inhibitor, which targets all three AKT isoforms at low nanomolar concentrations and is active against additional kinases from the AGC (cyclic AmP-dependent, cGmP-dependent and protein kinase C) kinase family 75 .
To address a major issue regarding the potential benefits of isoform specificity, a number of allosteric AKT inhibitors have recently been identified through screening of compound libraries and application of an iterative analogue library synthesis approach. These allosteric AKT inhibitors have shown some level of isoform selectivity (reviewed in ReF. 76 ). AKTi-1/2, a naphthyridinone allosteric dual inhibitor of AKT1 and AKT2, has potent antitumour activity in tumour xenograft models, and its analogue mK2206 is in a Phase I trial in patients with locally advanced or metastatic solid tumours (FIG. 4; TABLe 2 ).
Xl418, a small molecule that inhibits AKT and S6K and has shown antineoplastic activity in preclinical studies, is in Phase I clinical trials in patients with advanced solid tumours (FIG. 4; TABLe 2 ). vQD-002 (triciribine phosphate monohydrate), a water-soluble tricyclic nucleotide, is currently being tested in Phase I clinical trials in patients with both solid and haematological malignancies (FIG. 4 ; TABLe 2). It was recently reported that this compound could play a part in reversing drug resistance in ovarian cancer in patients who had previously undergone chemotherapy 77 ; however, its mechanism of action is unclear.
Targeting mTOR. Although mTOR was only recently defined as a member of the PI3K pathway, it is the first node of the pathway to be targeted in the clinic. Rapamycin (also known as sirolimus) (Rapamune; wyeth), the prototypical mTOR inhibitor, is a bacterially derived natural product that was originally used as an antifungal agent 78 . It was subsequently found to have immunosuppressive 79 and, more recently, anti-neoplastic properties (reviewed in ReFs 21, [80] [81] [82] . Rapamycin associates with its intracellular receptor, FK506-binding protein 12 (FKBP12), which then binds directly to mTORC1 and suppresses mTOR-mediated phosphorylation of its downstream substrates, S6K and 4EBP1 (ReFs 21,80) . Analogues of rapamycin, such as temsirolimus (CCI-779/Torisel; wyeth) and everolimus (RAD001/Afinitor; Novartis) have been developed as anti-cancer drugs. These rapamycin analogues, sometimes referred to as rapalogues, inhibit mTOR through the same mechanism as does rapamycin, but have better pharmacological properties for clinical use in cancer. The results of many mTOR inhibitor studies in patients with cancer have been described (reviewed in ReF. 80) . AP23573 has been designated orphan drug status for the treatment of softtissue and bone sarcomas. Results from recent clinical studies with temsirolimus and everolimus used as single agents showed that these drugs improved survival in patients with advanced renal cell carcinoma, leading to approval of these compounds for this indication 80, 83 .
However, preliminary results with mTOR inhibitors in many other tumour types, including advanced breast cancer and glioma, indicated a low response rate 80 . mTOR also presents a potential second target -namely, its mTORC2 complex that functions as a PDPK2 and phosphorylates the C-terminus of AKT at ser473, an obligatory event for full activation of AKT 18 . Although the clinical importance of PDPK2 function in cancer is unknown, a recent study showed that mTORC2 is required for the development of prostate tumours that are induced by PTEN loss 84 . Therefore, a kinase inhibitor of mTOR that can target both mTORC1 and mTORC2 would be expected to block activation of the PI3K pathway more effectively than rapamycin. Recent studies have described torkinibs and torin1 -potent and selective ATP-competitive inhibitors of mTOR that inhibit both mTORC1 and mTORC2 complexes and impair cell growth and proliferation more effectively than rapamycin 85, 86 . Interestingly, however, the enhanced activity of these mTOR kinase inhibitors may not be due to mTORC2 inhibition. Instead, the enhanced activity seems to be due to more complete inhibition of mTORC1 activity, as indicated by measurements of mTORC1-dependent and rapamycin-independent 4EBP1 phosphorylation and cap-dependent translation 85, 86 . Two ATP-competitive mTOR inhibitors, OSI-027 and AZD8055, are currently in clinical trials in patients with advanced solid tumours and lymphoma (FIG. 4; TABLe 2).
It should also be noted that several kinases in the PI3K pathway are client proteins for the heat shock protein 90 (HSP90) 87, 88 . Therefore, compounds that inhibit HSP90, such as geldanamycin and its analogues, may have therapeutic effects mediated at least in part through inhibition of the PI3K pathway (reviewed in ReFs 68, 89, 90) .
Ongoing issues and challenges
Unravelling the specific roles of PI3K isoforms: implications for drug development. The two isoforms of class I PI3Ks that are most widely expressed outside of the immune system in mammals are p110α and p110β, both of which are expressed in almost all tissue and cell types. As both isoforms need to form a complex with the p85 adaptor to bind to RTKs, and both use the same substrates and generate the same lipid products, it was long thought that they functioned redundantly in cellular physiology. However, over a decade ago, it was found that mice with homozygous germline deletion of either p110α or p110β die early during embryonic development 91, 92 , suggesting distinct roles for each isoform during embryogenesis. more recently, several groups have created mice with conditional knockout of p110α and p110β and mice with germline knock-in of alleles that encode kinase dead p110α or p110β [93] [94] [95] [96] [97] [98] (TABLe 3) . Studies with these mice have revealed that the two PI3K isoforms have markedly different roles in cellular signalling, growth and oncogenic transformation (FIG. 5a) . The p110α isoform performs most of the functions that are commonly assigned to PI3K in the literature. For example, p110α is responsible for most of the signalling downstream of RTKs and oncogenes such as RAS and polyoma middle 
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T antigen 94, 99 . Ablation of p110α resulted in substantially reduced AKT phosphorylation in response to stimulation by various growth factors, including insulin, epidermal growth factor (EGF) and insulin-like growth factor 94 . Cells that are deficient in p110α are resistant to oncogenic transformation induced by oncogenic alleles of RTKs 94 . Conversely, ablation of p110β has little effect on AKT phosphorylation in response to RTK signalling 93 . Instead, p110β, like p110γ, preferentially transduces signals from GPCRs through a mechanism that has yet to be elucidated 93, 95, 96 . As p110γ expression is largely limited to leukocytes whereas p110β has a broad tissue distribution, p110β may play an essential part in coupling GPCR signals to the PI3K pathway in cells or tissues outside of the immune system. In addition, p110β has been shown to have an important role in integrin-mediated platelet adhesion and arterial thrombosis 100 . Interestingly, p110β also seems to possess important kinase-independent functions 93, 95 .
There is considerable evidence indicating that targeting a single isoform of PI3K or other pathway members may be sufficient to block a particular tumour type, suggesting the potential desirability of generating isoform-specific inhibitors. Drugs that target single isoforms might avoid toxicity to the immune system, which is largely dependent on p110δ and p110γ for function. Similarly, because p110α and p110β seem to have distinct roles in multiple cellular processes (FIG. 5a) , it is possible that a drug aimed at either target would have fewer side effects than one that inhibits both. As p110α is important for the growth and maintenance of numerous tumours that feature PI3K activation, several companies are already generating p110α isoform-specific inhibitors (reviewed in ReFs 63, 68, 101) . It is hoped that these compounds will bypass the problems of inhibiting p110γ and p110δ while targeting the PI3K pathway in many tumour types.
Interestingly, recent studies on genetically engineered mouse models and chemical inhibitors, as well as limited short hairpin RNA experiments, suggest that tumours driven by PTEN loss may be sensitive to inhibition of p110β rather than p110α 93, 102, 103 . The exact mechanism by which p110β drives PTEN-null tumours has not been elucidated. Perhaps ligands such as lysophosphatidic acid that activate GPCRs drive PI3K activation in PTEN-null tumours, or perhaps PTEN loss allows a p110β-specific mechanism of basal PtdIns(3,4,5)P 3 synthesis to drive tumour formation 93 . It may be beneficial to consider the generation of p110β-selective compounds, especially as p110β seems to have a smaller role in insulin action than p110α 93, 95 . There are a few inhibitors -for example, TGX-115, TGX-286 and TGX-221 -which are selective for p110β relative to all other PI3K isoforms except p110δ 64, 100 . Among them, TGX-221 is perhaps the p110β-selective tool compound that is most commonly used to investigate p110β functions. It was shown to inhibit platelet aggregation and thrombosis 100 and is also capable of suppressing the activation of PI3K and proliferation of PTEN-null cancer cells 103 . Further preclinical development of p110β-selective inhibitors is necessary to improve their pharmacological properties. However, there is evidence that not all tumours that are driven by PTEN loss are dependent on p110β, and the presence of other genetic alterations is likely to change the PI3K isoform-dependence of these PTEN-null tumours (FIG. 5b) . For example, a number of tumour cell lines that feature loss of PTEN in conjunction with activating mutations in p110α are sensitive to loss of p110α and not to a loss of p110β 103, 104 . Given the essential roles of p110α in cellular physiology, the development of inhibitors specific for the mutant form of p110α that is found in tumours would be a particularly attractive route to therapy. Such inhibitors would presumably minimize side effects (that is, alteration in insulin signalling) that will almost certainly be associated with inhibition of the wild-type p110α, especially during prolonged treatment. It remains a great challenge for researchers to identify mutant-specific small-molecule inhibitors that target the catalytic centre of the mutant but not the wild-type kinase. The structure of a complex between wild-type p110α and the iSH2 An association between chronic inflammation and cancer is indicated. b | Schematic of phospho inositide 3-kinase (PI3K) isoform-selective inhibition in the treatment of cancers that feature specific oncogenic alterations. Recent studies suggest that p110β is a primary target for PTEN (phosphatase and tensin homologue)-deficient cancers. However, in the case of oncogenic alterations -such as RTK amplification or mutation, RAS mutation or activating mutations in the PI3K catalytic subunit α-isoform gene (PIK3CA) -the PI3K signalling largely depends on p110α, perhaps even in the absence of PTEN. PtdIns(3,4,5)P 3 , phosphatidylinositol-3,4,5-trisphosphate; PtdIns(4,5)P 2 , phosphatidylinositol-4,5-bisphosphate.
domain of p85 has recently been reported 52 . It reveals many features that are common to well-characterized protein kinases, including a hydrophobic ATP-binding pocket. most small-molecule inhibitors targeting PI3Ks that are currently in development work by binding to the ATP-binding pocket and thus competing with ATP, which is the mechanism of most protein kinase inhibitors. The structure of wild-type p110α suggests that the H1047R mutation in the kinase domain improves substrate binding through a direct effect on the conformation of the activation loop. Given the proximity of the activation loop to the ATP-binding pocket, the generation of an inhibitor that is specific for a kinase domain mutant might be feasible using existing drug scaffolds. It could be more difficult to target the mutated helical domain of the kinase (E542K or E545), as these mutations seem to affect protein-protein interaction by eliminating an auto-inhibitory contact with the iSH2 domain of p85
The effects of feedback loops, pathway crosstalk and signalling circuitry on therapeutic outcomes. A hallmark of signalling networks is the presence of multiple nodes with feedback loops and crosstalk between pathways. Two negative feedback loops have been described, involving S6K and Jun N-terminal kinase (JNK), which attenuate insulin-induced PI3K activation through IRS1 (ReFs 105-107) . S6K-or JNK-knockout mice show increased insulin sensitivity in response to high-fat diets compared with wild-type mice 108, 109 . Perturbing these feedback loops can have dramatic effects on drug responses, as exemplified by the response of certain tumours to rapalogues. when mTOR is activated, it can initiate a signalling cascade through S6K1 that results in a feedback loop which downregulates PI3K and AKT activity. Therefore, when tumours in which this loop is activated are treated with rapalogues, the net effect can be increased AKT activity, which can ultimately enhance tumour growth 110 . PI3K or AKT inhibitors should not cause this problem, but may suffer from issues that arise from crosstalk with other pathways. Specifically, in cancers bearing mutant RTKs, or oncogenes such as RAS that activate both the RAF-mitogenactivated protein kinase (mAPK) and PI3K pathways, blocking the PI3K pathway can actually upregulate signalling of the RAF-mAPK pathway because the two pathways have cross-inhibitory effects 111 . RAF-mAPK pathway signalling can in turn drive tumour growth, counteracting the effect of the PI3K pathway inhibition. It was recently shown that mTORC1 inhibition led to the activation of mAPK in a PI3K-dependent manner, providing another example of such signalling feedback loops and crosstalk 112 . As discussed below, combined inhibition of both pathways for therapy may alleviate this problem.
Identifying biomarkers that predict drug responses. For PI3K pathway inhibitors, as with all targeted therapies, it is crucial to develop clinically tractable biomarkers that are predictive of drug response. Biomarkers for PI3K pathway inhibitors can be divided into two categories:
those that indicate drugs are reaching intended targets in the PI3K pathway, and those that can be used to accurately predict which patients are likely to respond. Readily obtainable tissues, such as skin, hair follicles and peripheral blood mononuclear cells, have been used as surrogate tissues to assess the effect of PI3K inhibitors that are currently undergoing clinical trials 113 . The molecular markers of PI3K inhibition that are commonly used in the clinic are the levels of phosphorylated AKT and phosphorylated S6K1 in biopsies of these surrogate tissues and, when possible, tumour tissue. However, there is great variability in the robustness and reproducibility of the use of biomarkers for measuring the efficacy of PI3K pathway inhibitors. Thus, identification of new and potentially more robust biomarkers is a crucially important part of the preclinical development of PI3K inhibitors and in the conduct and interpretation of clinical studies using these inhibitors.
Preclinical studies have indicated that PI3K and AKT inhibition can be assessed by measuring blood insulin levels, which are increased owing to disruption of insulin signalling through the PI3K-AKT pathway 64, 98, 114, 115 . Studies in mice in which PI3Ks or AKT is genetically inactivated 93, 95, 98, 114 also suggested that changes in blood glucose levels in response to PI3K inhibition may be exploited clinically. However, early clinical results suggest that these effects might be transient and difficult to measure. The PI3K pathway plays a major part in insulinmediated glucose transport and metabolism, and so inhibition of the PI3K pathway in tumours can be measured by scanning positron emission tomography with fluorodeoxy-d-glucose as a probe. A recent study showed that the effect of BEZ235 in decreasing tumour vasculature permeability could be monitored by dynamic contrastenhanced magnetic resonance imaging 116 . These types of molecular imaging offer a minimally invasive approach to determine the efficacy of targeted PI3K inhibition 117 , and could be predictive of clinical outcome.
Sensitivity and resistance to PI3K-targeted therapies.
One of the key lessons drawn from targeted therapies has been the importance of matching the therapy to the patient. The presence of an activating mutation or other genomic alteration in the targeted kinase is perhaps the most accurate predictor of potential success. Examples include the use of imatinib (Gleevec; Novartis) to treat patients with chronic myelogenous leukaemia (Cml) featuring BCR-ABL fusions; trastuzumab (Herceptin; Genentech/Roche) and lapatinib (Tyverb; GlaxoSmithKline) to treat patients with breast tumours expressing human epidermal growth factor receptor 2 (HER2; also known as ERBB2); and gefitinib (Iressa; AstraZeneca) and erlotinib (Tarceva; Genentech/OSI/ Roche) for patients with lung cancer bearing mutations and/or amplification of the EGF receptor. This logic suggests that PI3K inhibitors will be effective in tumours that feature activating mutations in p110α or loss of PTEN, and AKT mutations will sensitize a tumour to AKT inhibitors. It also seems likely that targeting a pathway immediately downstream of the genetic alteration will be effective. Therefore, inhibitors of PI3K and AKT Biomarker A characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention.
could be useful for the treatment of tumours that feature activated RTKs or oncogenic RAS (perhaps in combination with inhibitors of RAF and mAPK). Finally, inhibitors of mTOR and kinases further downstream in the pathway might also be effective in tumours that feature PI3K activation. However, it is not clear how distant a mutation can be from the targeted node in the pathway and it still be sensitive to the inhibition.
Because most tumours are genetically complex, it is likely that alterations in genes other than those encoding PI3K will predispose a tumour to be sensitive or, even more likely, resistant to PI3K-targeted therapy. An obvious source of resistance is a mutation or amplification of a downstream pathway component. Just as mutations of p110α or loss of PTEN can render HER2-positive tumours resistant to trastuzumab 118, 119 , it is likely that tumours with amplifications or mutations in various downstream kinases will block the action of inhibitors that target their upstream components. It is therefore important to identify and select patients who are likely to respond to PI3K-targeted cancer therapy.
These resistance events can be either primary or acquired during therapy. For example, so-called 'gatekeeper' mutations may occur after targeted protein kinase therapy (reviewed in ReF. 120) . These mutations occur in the kinase domain of the targeted kinase, at an amino-acid residue known as the gatekeeper, and block binding of the inhibitor while allowing catalysis to proceed. A functional screen against a structurally diverse panel of PI3K inhibitors has identified a potential 'hot spot' for resistance mutations in p110α, but surprisingly found a lack of resistance mutations at the gatekeeper residues 121 . Other known resistance mechanisms include the activation of alternative pathways, such as the induced gefitinib resistance through reactivation of HER3 signalling in lung cancer as a result of incomplete HER2 inhibition or amplification of hepatocyte growth factor receptor (also known as mET) [122] [123] [124] . A comparable mechanism in the case of PI3K inhibitors would be the activation of the RAF-mAPK pathway discussed above. Current preclinical research and clinical studies will undoubtedly reveal more resistance mechanisms and facilitate the development of therapeutic strategies to overcome drug resistance.
Emerging candidates and approaches
The effectiveness of simultaneously targeting two kinases in the pathway. A number of the early PI3K inhibitor clinical candidates are dual-specificity drugs, targeting not only several PI3K isoforms but also the kinase activity of mTOR (FIG. 4; TABLe 2 ). It was easy to generate this class of compounds because mTOR is in the PI3K superfamily and so bears considerable structural similarity to class I PI3Ks. A strong argument can be made that by targeting two nodal points in the pathway concurrently, a compound may be more efficacious than if it has only a single target (FIG. 3) . For example, PI-103 was found to be a potent inhibitor of both PI3K and mTOR, and was unexpectedly effective at blocking the growth of aggressive glioma cells in vivo and in vitro 65 . A second class of inhibitors that selectively target particular tyrosine kinases and PI3Ks has been described 125 . A single agent with dual specificity may have the added advantage of being less likely to induce drug resistance than monospecific agents. Clinical resistance to a kinase inhibitor often arises through second-site mutations in the targeted kinase. Targeting two kinases simultaneously greatly diminishes the possibility of resistance, as it is unlikely that a given tumour can generate two resistant kinases during the course of a single drug treatment. Of course, this assumes that both kinases are essential for tumour survival and/or growth.
Combining PI3K pathway inhibitors with drugs that target other pathways. Although knockout of PI3K isoforms can block oncogenic transformation that is driven by various activated RTKs and oncogenes 93, 94 , targeting PI3K may not be sufficient to cause regression of established tumours. For example, mice in which p110α was mutated to ablate its binding to RAS are resistant to lung tumour development driven by activated KRAS 126 . However, the same KRAS lung tumour model is insensitive to PI3K inhibition by BEZ235 after the tumours have formed. In this case, a combination of PI3K and RAF pathway inhibition by BEZ235 plus a mEK1 (mAPK kinase 1) and mEK2 inhibitor (ARRY142886; also known as ADZ6244), effectively induced tumour regression in mice 127 . Consistent with these findings, activation of the mEK effector pathway downstream of RAS was found to be responsible for resistance to PI3K inhibitors in tumour cell lines harbouring RAS mutations. Therefore, the combination of mEK inhibitors and PI3K inhibitors synergistically blocked growth of tumour cells that expressed oncogenic RAS 102, 128 . Recent comprehensive genomic studies in cancer have revealed that tumours with PI3K mutations or PTEN loss often harbour other genetic alterations that can act independently to promote tumour development (reviewed in ReF. 129) . The presence of these or other genetic alterations is likely to change the sensitivity of tumours to PI3K inhibition. Therefore, combinations of PI3K inhibitors with other targeted drugs may achieve optimal clinical benefits (FIG. 3a) .
Angiogenesis as a specific target of the PI3K pathway. Interestingly, inhibition of the PI3K pathway may be effective against tumours by two distinct mechanisms: by directly blocking tumour cell growth and by inhibiting tumour angiogenesis. It is notable that the PI3K pathway plays an important part in the production of vascular endothelial cell growth factor (vEGF) and in the signalling of the vEGF receptor (vEGFR), which is important for angiogenesis. Rapamycin and its analogues have been studied most extensively in the clinic as anti-angiogenic agents. Rapamycin was found to have anti-angiogenic activities associated with markedly reduced production of vEGF, and it completely abrogated the response of vascular endothelial cells to stimulation by vEGF 130 . when used at low (minimally immunosuppressive) doses, rapamycin significantly inhibited the growth of established vascularized tumours 130 . This work indicated that rapamycin might affect tumour
Tumour angiogenesis
The formation of new blood vessels that grow into the tumour, supplying nutrients and oxygen to assist tumour growth.
growth primarily through its anti-angiogenic properties, leading to the suggestion that it could be particularly effective in treating highly vascularized tumours. Indeed, rapamycin significantly inhibits the progression of Kaposi's sarcoma in which the driving oncogenic alteration is presumed to be activated vEGF-vEGFR signalling 131 . In renal cell carcinoma, loss of the von Hippel-lindau tumour suppressor (VHL) that normally inhibits HIF1A (hypoxia-inducible factor 1, α subunit) leads to enhanced vascularization and sensitizes cancer cells to the mTOR inhibitor CCI-779 (ReF. 132) . From a mechanistic perspective, rapamycin inhibits mTORC1-dependent translation and action of HIF1A, and thereby decreases vEGF production 133, 134 . Data from preclinical studies in tissue culture and mouse models suggest that an anti-angiogenic effect may well contribute to the anti-tumour effects of inhibiting PI3K or AKT 97, 116, 129, 135, 136 . Recently, it was shown that genetic ablation of class IA PI3K specifically in the endothelium resulted in impaired vessel integrity during development as well as tumour angiogenesis in mice 129 . Furthermore, it has been shown that angiogenesis specifically requires the p110α isoform, as it is crucial in mediating vEGF signalling and controlling endothelial cell migration 97 . Indeed, inhibition of tumour vasculature development in xenograft tumour models by BEZ235, a dual PI3K-mTOR inhibitor, was correlated with inhibition of PI3K and AKT, but not with inhibition of mTORC1 (ReFs 116, 129) . It is quite possible that PI3K or AKT inhibitors may be as effective as rapamycin analogues in the treatment of highly vascularized tumours.
Conclusions and future directions
The PI3K pathway clearly presents both a great therapeutic opportunity and a tremendous challenge for cancer therapy. As compounds that target PI3K (or AKT and mTOR) progress through clinical trials, potential issues associated with toxicity and resistance can be expected. PI3K mutants that are resistant to a kinase inhibitor may arise during treatment, as has been seen for BCR-ABl inhibition by imatinib in the treatment of Cml. Oncogenic changes in other components in the PI3K pathway, or other parallel and/or interconnected pathways, may also render cancer cells resistant to PI3K inhibition. It is therefore important to identify new therapeutic targets for the development of drugs that may be used either in place of PI3K inhibitors or to enhance the efficacy of PI3K inhibitors at subtoxic doses.
Finally, it is worth noting that reduced expression of PDPK1 (ReF. 137) , AKT1 (ReF. 138) or p110α (T.m.R. and J.J.Z., unpublished observations) can suppress tumour formation in animal models. This suggests that it might be possible to use low levels of inhibitors of these enzymes to block tumorigenesis in certain circumstances. Familial diseases such as Cowden's syndrome, which features germline loss of PTEN, might be treated in this manner. If the inhibitors are present before tumour initiation, cancer chemoprevention could be possible. Similarly, a chemopreventative approach might work to block outgrowth of cells that have metastasized to distant sites after successful treatment of a primary tumour. Further experimentation will be required to determine whether there are doses that are sufficient to block tumour outgrowth but engender only minimal side effects during long-term therapy.
